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A Diltiazem kinetic spectrophotometric UV–Vis method, based on a reaction of the Diltiazem with hidroxylamine and a ferric salt, was used for
the quantification of Diltiazem in different pharmaceutical formulations. This method is based on the acquisition of three-way data structures
[wavelength (nm)×time (s)×concentration (mg/L)] followed by chemometric analysis by an appropriate PARAFAC2 or MCR-ALS second-order
calibration model. The results obtained are compared with those obtained by direct determination, at maximumwavelength, and by the United States
Pharmacopeia (USP) standard chromatographic method. For all the pharmaceutical formulations analysed good quantification results were found
with PARAFAC2 and MCR-ALS second-order calibration models. For bulk drug analysis, detection limits of 6 and 2 mg/L, and for pharmaceutical
formulations analysis, an average detection limit of 41 and 39 mg/L were found, respectively with PARAFAC2 and MCR-ALS.
© 2007 Elsevier B.V. All rights reserved.Keywords: Diltiazem antihypertensor; Kinetic UV–Vis spectroscopy; Quantification; Bulk drug; Pharmaceutical formulations; PARAFAC2; MCR-ALS1. Introduction
Diltiazem, one of the major cardiovascular drug, is a calcium
channel blocker widely use as an anti-anginal and anti-
hypertensive agent [1,2]. The analysis of therapeutic compounds
in pharmaceutical formulations constitutes a mixture analysis
problem because these formulations always contain excepients.
In the United States Pharmacopeia (USP) the official method for
the determination of Diltiazem in bulk drug, in extended-release
capsules and in tablets formulations is a HPLC-UV method [1].
In the European Pharmacopeia the official method for the
determination in bulk drug is a potentiometric titration [2].
Several methods were developed for its quantification but
most of the methods for the determination of Diltiazem in bulk
drug, pharmaceuticals formulations and biological fluids are
based in chromatographic separative techniques [3–15]. The
spectrophotometric methodologies are a good alternative to the
separative techniques due to cheaper and lower time of analysis⁎ Corresponding author. Fax: +351 226082959.
E-mail address: jcsilva@fc.up.pt (J.C.G. Esteves da Silva).
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doi:10.1016/j.chemolab.2007.06.003and to the generation of few waste products. Some spectropho-
tometric methods, based on derivatisation reactions, were
developed for Diltiazem quantification in bulk drug and
pharmaceutical formulations [16–22]. To some of these methods
a reaction time of about 40 min was observed [16,17] and with
others an extractive step is needed [18–22].
In this paper a new method for the quantification of Diltiazem
in pharmaceutical formulations with a lower time of analysis, no
extractive step and maximum sensitivity, based on a previously
optimized colour development reaction, is presented [23]. The
acquisition of a spectrum as function of the reaction time and
concentration of Diltiazem (standards and samples) allows the
arrangement of the data set to a third order tensor. Besides the
chemical selectivity obtained by the colour development reaction
a further improvement of selectivity can be obtained with multi-
way chemometric analysis of the experimental data. With this
approach neither the extraction nor the separation of the analyte
from the background are needed.
Several second-order models, with different trilinearity
assumptions, can be used for multi-way analysis. In this paper
two models will be used: parallel factor analysis 2 (PARAFAC2)
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(MCR-ALS) [25]. Both models, in a different way, allow small
deviations to the trilinear model. PARAFAC2 allows deviation of
the trilinearity in one dimension and MCR-ALS allows deviation
of the trilinearity in all the components or in some of them.
Several methods have been proposed for the analysis of
three-dimensional kinetic spectrophotometric data obtained by
different experimental procedures [26–32]. Besides models that
allow deviations to the trilinearity of three-dimensional data, as
PARAFAC2 [26,27], MCR-ALS [28–31] and three-dimension-
al Tucker (TUCKER3) [32], models that assume rigorous
trilinear three-dimensional data, as parallel factor analysis
(PARAFAC) [26,28,33–39], trilinear decomposition (TLD)
[36] and the n-way partial least squares (NPLS) [28,33,35,38]
have been proposed for the analysis of this kind of data.
The objective of this paper is to propose a new method for
the analysis of Diltiazem in pharmaceutical formulations based
on a three-dimensional kinetic spectrophometric method
coupled to chemometric decomposition methods of PAR-
AFAC2 and MCR-ALS. Four pharmaceutical formulations
were used to assess the performance of the new methodology
and the results were compared with those obtained by a USP
standard chromatographic method.
2. Experimental
2.1. Reagents
Diltiazem reference standard (≥99%purity), ammonium ferric
sulphate (99% purity) and hydroxylamine hydrochloride (98%
purity) were obtained from SIGMA-ALDRICH Química S. A.
(Spain). Sodium hydroxide and methanol for liquid chromatog-
raphy were purchased from Merck, Darmstadt (Germany).
Deionised water with resistivity higher than 4 MΩ/cm was used.
Pharmaceutical formulations with different dosage, from 60
to 200 mg of Diltiazem, were chosen for this study. The
pharmaceutical formulations were Alandiem® tablets 60 mg
from Zimaia (Al60ta), Balcor® Retard capsules 90 mg from
Baldacci (Ba90re), Herbesser® SR 120 extended release
capsules 120 mg from Delta (He120sr) and Diltiem®AP 200
extended release capsules 200 mg from Sanofi (Dtap).
2.2. Solutions
Previous to the preparation of the Diltiazem standard stock
solutions by rigorous weighting of the solid powder, Diltiazem
was dried during two hours in an oven at 105 °C.
For the quantification with a previously optimized kinetic
spectrophotometric UV–Vis method [23] a 4000 mg/L Diltiazem
standard stock solution prepared in methanol, was used. Aqueous
solutions prepared by rigorous weighting of hydroxylamine
hydrochloride (18.750%) and sodium hydroxide (37.500%) and
perchloric acid 7.000% (w/w) solutions of ammonium ferric
sulphate (2.000%) were also used. The hydroxylamine reagent
(hydroxilamine 9.375% / sodium hydroxide 18.750%) used for
the colour development reaction was obtained by mixing equal
volumes of the aqueous hydroxylamine hydrochloride (18.750%)and sodiumhydroxide (37.500%) solutions. The sample solutions
were prepared by rigorous weighting of a mass equivalent to one
tablet or capsule from amixture of 20 tablets or capsules, obtained
after grounding and homogenization, in methanol for a final
concentration of 4000 mg/L. To separate insoluble excepients
present in the pharmaceutical formulations, sample solutionswere
centrifuged at 13000 rpm during 10 min.
All the dilutions were obtained with methanol for a final
volume of 2.5 mL in the 1 cm quartz cells used for spectra
acquisition. Except for the perchloric acid addition the different
dilutions of the reagents in the different concentrations used
were obtained by adding a fixed volume of the initial solutions.
For the quantification with the USP chromatographic method
the mobile phase, standard stock solutions and sample solutions
were prepared according the USP recommendations [1]. The
mobile phase is prepared as amixture of a buffer solution (1.16 g of
d-10-camphorsulonic acid in 1000 mL of 0.1 M sodium acetate
adjusted to pH 6.2 with sodium hydroxide), acetonitrile and
methanol (50:25:25). The standard stock and sample solutionswere
prepared in methanol by rigorous weighting for a final concentra-
tion of 2000 mg/L. Diluted standard and sample solutions were
obtained by dilution with methanol to the required concentrations.
2.3. Instrumentation
Spectral acquisition was made in a Hewlett-Packard
HP8452A diode-array spectrophotometer in advanced mode.
Spectra were collected with the shutter open, wavelength range
from 400 to 800 nm with a 2 nm interval, run time 30 s, cycle
time 1 s and an integration time 0.5 s.
HPLC determinations were made with a system constituted
by a HP1100 isocratic pump, a manual injection valve
Rheodyne model 7752i, a Rheodyne 20 μL loop, a pre-column
Agilent (20 mm×4 mm) coupled to a Supelco column
(100 mm×4.6 mm) Hypersil® ODS with 3 μm particle
diameter and a diode array detector (DAD) Ati Unicam Crystal
250 model. The DAD acquired spectra in a wavelength range
from 220 to 472 nm with a resolution of 2 nm.
2.4. Analytical methodologies
The quantification of Diltiazem with the kinetic spectropho-
tometric UV–Vismethodwas performed in a 1 cm quartz cells for
a total volume of 2.5 mL with a standard addition method with
four experimental data points. For an expected concentration of
150 mg/L of Diltiazem in bulk drug and in pharmaceutical
formulations solutions, and in order to obtain Diltiazem standard
concentrations of 50, 150 and 250 mg/L, additions of 30, 90 and
150 μL of the 4000 mg/L Diltiazem standard solution were done.
Within the quartz cell the mixture of the reagents is done by
stirring with a micro magnetic bar. The order of reagents addition
is: (i) suitable volume of Diltiazem bulk drug or pharmaceutical
formulation solution; (ii) suitable volume ofmethanol to 0.500mL
(attending to the previous added volume); (iii) 0.300 mL of
hydroxylamine reagent; (iv) suitable volume of methanol to
2.5 mL (attending to the all the volumes added); (v) minimum
volume of perchloric acid 7.000% to neutralize the sodium
Table 1
Quantification of the bulk drug with UV–Vis direct, UV–Vis PARAFAC2, UV–
Vis MCR-ALS and HPLC-UV methodologies⁎
UV–Vis (CExpected=150.0 mg/L)
Direct PARAFAC2 MCR-ALS
CEstimated
(mg/L)
156.7 (4.9) 143.7 (3.0) 150.5 (1.1)
Recovery
(%)
104.5 95.71 100.3
DL (3sy/x/b) 9.943 6.318 2.271
Model evaluation
Fit (%) – 99.487 97.338
SSQr – 0.084 2.087
Iterations – 2000 (maximum) 28
RSpectrum – +0.711 +0.842
RReaction time – +0.592−+0.526 +0.701−+0.701
+0.358−+0.415 +0.701−+0.701
Calibration (y=bx+a, m=4)
a 0.3156 (0.0051) 0.2625 (0.0030) 0.2205 (0.0009)
b 2.014×10−3
(3.475×10−5)
1.827×10−3
(2.003×10−5)
1.465×10−3
(5.772×10−6)
sy/x 6.674×10
−3 3.848×10−3 1.109×10−3
RConcentration 0.9997 0.9999 1.0000
HPLC-UV (n=3, CExpected=100.0 mg/L)
CEstimated
(mg/L)
98.80 (0.65)
Recovery
(%)
98.80
DL (3sy/x/b) 14.98
⁎The values in brackets are the standard deviation of the extrapolated concentration,
intercept and slope calculated with two degrees of freedom; CEstimated,
concentration estimated; DL, detection limit; Fit, model fit; SSQr, sum
squares of residuals; RSpectrum, calculated correlation coefficient between
the estimated and the rough spectrum of the principal coloured product;
RReaction time, calculated correlation coefficient between the estimated and
the rough reaction time profile of the principal coloured product; m,
number of experimental data points for calibration; sy/x, standard deviation
of the residuals; RConcentration, is the calculated correlation coefficient
between the estimated and expected concentrations of the principal
coloured product; n, number of determinations.
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ammonium ferric sulphate. The addition of ammonium ferric
sulphate is made after the acquisition of the spectra has started.
The chromatographic quantification of Diltiazem with the
USP method (flow rate of 1.6 mL/min and detection at 240 nm),
following the USP recommendations, was performed using an
external standard method of calibration. The quantification for
each of the samples, bulk drug and pharmaceutical formula-
tions, was done with three determinations.
2.5. Chemometric analysis
The three-way data structures are obtain by the acquisition of
UV–Vis spectra as function of the reaction time following the
kinetic reaction and at different concentrations of Diltiazem
obtained by a standard addition method [wavelength× time×-
concentration]. For the direct determination of Diltiazem the
absorbance intensity values at maximum wavelength are
collected from the matrix of experimental data.
The two second-order models used in the analysis of the
three-way data structure are the PARAFAC2 and the MCR-ALS
models [24,25]. PARAFAC2 model of K matrices arranged as a
third order tensor is defined as Eq. (1):
Xk ¼ ADk Pk4Hð ÞTþEk ¼ ADkBTk þ Ek ; k ¼ 1; N K ð1Þ
Xk is the k matrix of the K matrices (X1, …,Xk), A is the first
dimension loadings (I×N) matrix where N is the number of
components, Dk is the diagonal matrix with elements from 1 to
N that holds the kth row of the third dimension loadings C
(K×N) matrix, H is an (N×N) scaling matrix, Pk is an
orthonormal (J×N) matrix in which J can vary with K and Ek is
the K matrix of the residuals three-way data structure of K
matrices. The Bk is the (J×N) Kmatrix of the second dimension
loadings obtained by of Pk⁎H.
MCR-ALS model of K matrices (X1,…,Xk) arranged as a
bidimensional column-wise data matrix is defined as Eq. (2):
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Xk′ is the column-wise bidimensional data matrix of the K
matrices of the three-way data structure, Ak is the first and third
dimension loadings (L×N) matrix where L= I×K and N is the
number of components, BT is the second dimension loadings
(N×J) matrix and Ek is a L×N matrix of residuals.
The data matrices initially analysed with PARAFAC2 were
structured as three-way data structures [wavelength (nm)×time
(s)×concentration (mg/L)] andwithMCR-ALSwere structured as
column-wise bidimensional data structures [(concentration (mg/
L)×time(s))×wavelength (nm)]. For the MCR-ALS model data
matrices structured as column-wise bidimensional data [(concen-
tration (mg/L)×wavelength (nm))×time(s)] were also analysed.
The estimations in the two models were obtained using an
iterative alternating least squares regression with the two modelsusing the adequate constraints. The initial estimates used for the
two models were estimates of a model without constraints. In
order to obtain the initial estimates of the models without
constraints an initial analysis with the PARAFAC2 model was
performed with initial estimates of SVD and with theMCR-ALS
model with initial estimates of pure variables obtained by
SIMPLISMA (SIMPLe-to use Interactive Self-modelling Mix-
ture Analysis). The analysis of the data structures was performed
with non-negativity constraints in the first and third dimensions
for the PARAFAC2 model and in the two dimensions for the
MCR-ALS model. With the MCR-ALS model other natural
constraints as the trilinearity constraint were used. As conver-
gence criteria a value of 1×10−7 and 1×10−3 and a maximum
number of iterations of 2000 and 50 were used respectively with
the PARAFAC2 and MCR-ALS.
The model evaluation was done with the model fit, sum
squares of residuals (SSQr) and the iterations number. The
Table 2
Quantification of the pharmaceutical formulations with UV–Vis direct, UV–Vis
PARAFAC2, UV–Vis MCR-ALS and HPLC-UV methodologies⁎
Pharmaceutical formulations
Al60ta Ba90re He120sr Dtap
UV–Vis direct (CExpected=150.0 mg/L)
CEstimated
(mg/L)
155.2 (10.8) 152.5 (16.3) 154.9 (14.4) 155.5 (23.4)
Recovery
(%)
103.7 101.4 103.3 103.1
DL (3sy/x/b) 21.90 33.32 29.06 47.45
DOSEstimated 62.95 91.22 123.9 206.3
PE (%) 15.20 12.99 12.02 4.00
RConcentration 0.9986 0.9967 0.9975 0.9933
UV–Vis PARAFAC2 (CExpected=150.0 mg/L)
CEstimated
(mg/L)
138.9 (7.4) 132.5 (16.7) 137.6 (26.7) 147.3 (25.1)
Recovery
(%)
92.81 88.04 91.72 97.73
DL (3sy/x/b) 15.78 36.56 57.41 52.12
DOSEstimated 55.68 79.33 110.1 195.5
PE (%) 1.901 2.916 0.506 1.462
Model evaluation
Fit (%) 99.32 99.56 99.70 99.66
SSQr 0.129 0.038 0.026 0.020
Iterations 2000
(maximum)
2000
(maximum)
2000
(maximum)
2000
(maximum)
RSpectrum +0.695 +0.962 +0.913 +0.910
RReaction time −0.548 −
−0.038
+0.869 −
+0.936
+0.294 −
−0.024
+0.119 −
+0.181
−0.142 −
−0.373
+0.924 −
+0.905
+0.918 −
+0.909
+0.750 −
+0.083
RConcentration 0.9993 0.9960 0.9902 0.9919
UV–Vis MCR-ALS (CExpected=150.0 mg/L)
CEstimated
(mg/L)
137.4 (3.3) 142.6 (12.2) 137.4 (15.7) 146.8 (42.3)
Recovery
(%)
91.83 94.77 91.58 97.16
DL (3sy/x/b) 7.165 25.78 33.94 88.41
DOSEstimated 55.10 85.29 109.9 194.7
PE (%) 0.835 4.500 0.654 1.834
Model evaluation
Fit (%) 96.49 97.24 97.34 95.90
SSQr 3.442 1.504 1.981 2.783
Iterations 47 26 14 14
RSpectrum +0.840 −
+0.840
+0.972 +0.860 +0.982
+0.840 −
+0.840
RReaction time −0.423 +0.960 −
+0.960
+0.924 −
+0.924
+0.934 −
+0.934
+0.960 −
+0.960
+0.924 −
+0.924
+0.934 −
+0.934
RConcentration 0.9998 0.9980 0.9966 0.9773
HPLC-UV (n=3, CExpected=100.0 mg/L)
CEstimated
(mg/L)
91.27 (1.03) 90.76 (3.88) 92.37 (1.72) 99.22 (3.09)
Recovery
(%)
91.08 90.69 92.18 99.18
DOSEstimated 54.65 81.62 110.6 198.4
Notes to Table 2
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Eq. (3) and for the MCR-ALS is defined according the Eq. (4).
PARAFAC2Fit kð Þ ¼ 100
 1
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
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 2
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0
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ð3ÞMCRQALSFit kð Þ ¼ 100 1
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ð4Þ
In Eqs. (3) and (4), respectively for the PARAFAC2 and
MCR-ALS models, xˆijk and xˆlj is the ijk and lj element of the
estimated data matrix and the xijk and xlj is the ijk and lj element
of the experimental data matrix.
Also, in order to evaluate the estimates obtained in the three
dimensions, the correlation coefficient of the estimates of the
principal coloured product is calculated for each of the
dimensions. The correlation coefficients were calculated between
the estimated spectra and the rough experimental spectra, between
the estimated reaction time profile and the rough experimental
time reaction profile and between the estimated concentrations
and the standard addition concentrations.
The evaluation of the quantification obtained by the UV–Vis
direct, PARAFAC2 and MCR-ALS methodologies was done by
comparison with the quantification obtained by the HPLC-UV
analytical methodology through the calculation of the prediction
error (PE). PE was calculated according the Eq. (5) attending to
the dosage obtained by each of these methodologies and the
dosage obtained by the HPLC-UVanalytical methodology.
PE kð Þ ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
Di Dˆi
 2
Dið Þ2
vuut  100 ð5Þ
In Eq. (5) Di is the dosage estimated by the USP HPLC-UV
methodology and Dˆi is the dosage estimated by the direct,
PARAFAC2 or MCR-ALS methodologies. Also, in the pharma-
ceutical formulations, a comparison of the overall concentrations
estimated by the different methodologies was performed by the
paired t and the F two samples tests at 95% confidence level
( p=0.05).Notes to Table 2
⁎The values in brackets are the standard deviation of the extrapolated concentration
calculated with two degrees of freedom; CEstimated, concentration estimated; DL,
detection limit; DOSEstimated, Dosage estimated; PE, prediction error; Fit, model fit;
SSQr, sum squares of residuals; RSpectrum, calculated correlation coefficient
between the estimated and the rough spectrum of the principal culoured product;
RReaction time, calculated correlation coefficient between the estimated and the rough
reaction time profile of the principal coloured product; RConcentration, is the
calculated correlation coefficient between the estimated and expected concentra-
tions of the principal coloured product; n, number of determinations.
Table 3
PARAFAC2 and MCR-ALS model fit conditions used in the analysis of the pharmaceutical formulations
Three-way data structure
analysed
Components
number
Restrictions (PARAFAC2 in the 1st and 3rd and MCR-ALS
in the two dimensions)
Initial estimates Pharmaceutical
formulations
PARAFAC2 model fit conditions
Wavelength (nm)× time
(s)×concentration (mg/L)
4 Non negativity PARAFAC2 without
restrictions
Ba90re
5 Dtap and He120sr
4 SVD Al60ta
MCR-ALS model fit conditions
(Concentration (mg/L)× time
(s))×wavelength (nm)
3 Non negativity and trilinearity in the coloured compound MCR-ALS without
restrictions
Ba90re and He120sr
3 Non negativity and trilinearity in the coloured
and initial compounds
Dtap
(Concentration (mg/L)×
wavelength (nm))× time (s)
3 Non negativity and trilinearity in the coloured compound Al60ta
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methodologies, the corresponding detection limits (DL) were
estimated from the residuals standard deviation of the univariate
regression line of the absorbance (direct analysis) or the
concentrations estimates (PARAFAC2 and MCR-ALS) as
function of the Diltiazem concentrations of standards in the
calibration by the standard addition method. Similarly, an
estimative of the detection limit of the USP methodology was
obtained from the standard calibration curve.
PARAFAC2 and MCR-ALS procedures, implemented in
MATLAB code, were obtained from http://www.models.kvl.dk/
source/nwaytoolbox/ and http://www.ub.es/gesq/mcr/ndownload.
htm), respectively.
3. Results and discussion
3.1. Direct analysis
Tables 1 and 2, show the results of the direct UV–Vis, multi-way UV–
Vis and USP HPLC-UV analysis of the bulk drug and pharmaceutical
formulations, respectively. The comparison of the results obtained byFig. 1. Rough experimental spectrumand reaction time profile of aDiltiazem standard 150direct UV–Vis and by USP HPLC-UV methods present in these tables
shows that the direct analysis gives relatively high estimates for the
concentration of Diltiazem. For example, in the case of the bulk drug
analysis about 105% recoverywas obtainedwith direct analysiswhilewith
the HPLC method about 99% recovery was obtained. For the
pharmaceutical formulations higher differences are usually observed-the
direct analysis allows estimations between 101 to 104% recoverywhile the
HPLCmethod gives between 91 to 99% recovery. Prediction errors higher
than 12% are found by direct analysis for three of the four pharmaceutical
formulations evaluated. The high estimations obtained by direct analysis
are probably due to background effects, because the chemical background
of the samples is more complex, which will be corrected using multi-way
analysis. The concentrations estimated by direct and the estimated by
PARAFAC2 or MCR-ALS, evaluated by the paired t and the F tests, are
significantly different at 95% confidence level- the p values between the
direct and PARAFAC2 were 0.009 and 0.017, respectively, and between
the direct and MCR-ALS were 0.011 and 0.040, respectively.
3.2. Multi-way analysis
For the bulk drug and for some of the pharmaceutical formulations the
best estimated concentrations were found with the same model fit.0mg/L atmaximumabsorbance intensity (reaction time 4 s andwavelength 502 nm).
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obtained with a model of four components, non negativity and initial
estimates by a PARAFAC2 model without constraints in the analysis of a
three-way data structure [wavelength (nm)×time (s)×concentration (mg/
L)]. In the fit by this model the first and third component are the baseline
with background absorbance, the second component are the initial
compounds and the fourth component is the main coloured compound.
With MCR-ALS the best concentration estimations were obtained
with a model of three components, non negativity, trilinearity in the
coloured compound and initial estimates by a MCR-ALS model
without constraints in the analysis of a bidimensional data structure
[(concentration (mg/L)× time (s))×wavelength (nm)]. In the fit by this
model the first component are the initial compounds, the second
component is the main coloured compound and the third component is
the baseline with background absorbance.Fig. 2. Normalized scores and loading values estimated by the a) PARAFAC2 and b)
absorbance intensity with the time.Table 3 resumes the information about the multi-way model
characteristics in the analysis of the pharmaceutical formulations.
For each of the second-order calibration methods used the best
estimated concentration for three, PARAFAC2, and for two, MCR-
ALS, of the pharmaceutical formulations were obtained with
different model fit conditions. For better PARAFAC2 model
estimation and for the higher dosage pharmaceutical formulations
(He120sr and Dtap) a fifth component and for the lower dosage of
the pharmaceutical formulations (Al60ta) initial estimations by SVD
are needed. For better MCR-ALS model estimation and for the
highest dosage pharmaceutical formulation (Dtap) the trilinearity
constraint also in the initial compounds and for the lower dosage of
the pharmaceutical formulations (Al60ta) the analysis of the three-
way data structure [(concentration (mg/L)×wavelength (nm))× time
(s)] are needed.MCR-ALS models in the dimensions of the spectra and reaction time profile of
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estimative than those obtained by direct analysis. The prediction errors
found by PARAFAC2 and MCR-ALS methodologies are lower than
the prediction errors found by direct analysis. This result shows that
multi-way analysis compensates for the presence of background signals
and allows Diltiazem concentration estimations in pharmaceutical
formulations similar to the USP method. Also, PARAFAC2 always
gives higher model fits than MCR-ALS- PARAFAC2 originates fits of
about 99% while MCR-ALS originates fits of about 97%.
For the pharmaceutical formulations the concentrations estimated
by PARAFAC2 and MCR-ALS are not significantly different as
resulted from the analysis by the paired t and F test at 95% confidence
level— the p values were 0.519 and 0.313, respectively. Nevertheless,
for three of the four pharmaceutical formulations under analysis, lower
prediction errors are obtained with PARAFAC2.
The DL that characterize the four methods for Diltiazem quantifica-
tion are shown for the bulk drug in Table 1 and for the pharmaceutical
formulations in Table 2. For the bulk drug the multi-way methods have
the lowest detection limits with 6 and 2 mg/L for PARAFAC2 andMCR-
ALS, respectively- the USP chromatographic method has a DL of 15mg/
L. For the pharmaceutical formulations an average of the detection limit
of 33, 41 and 39 mg/L were found, respectively with direct, PARAFAC2
and MCR-ALS methodologies. For two of the pharmaceutical formula-
tions (Table 2) the lowest detection limit was found with MCR-ALS and
for the other two by direct analysis.
Fig. 1 shows the rough experimental spectrum and reaction time
profile and Fig. 2 shows typical results of the PARAFAC2 and MCR-
ALS spectral and reaction profiles components. Indeed, besides the
concentration estimations multi-way methods allow the estimation of the
spectra and reaction profiles of the components that constitutes the
samples under analysis. Attending to the obtained rough experimental
spectrum and reaction time profile and to the expected experimental
spectrum and reaction time profile a greater correlation coefficient for the
spectra and a lowest correlation coefficient for the reaction time profile
could be accepted as criteria of better estimates. As shown by theRspectrum
present in Tables 1 and 2, the absorbance spectra of the coloured product
of the reaction that constitutes the basis of the kinetic method can be well
estimated either by PARAFAC2 or MCR-ALS decomposition methods.
Also, the reaction profiles can be well estimated by these two methods.
Generally better spectra and reaction time profile estimates are found by
the MCR-ALS decomposition method.4. Conclusions
Diltiazem quantification in bulk drug and pharmaceutical
formulations by PARAFAC2 and MCR-ALS methodologies
gave similar results as those obtained by the USP standard
chromatographic method. Similar quantification results were
obtained with PARAFAC2 and MCR-ALS methodologies.
For good quantification of Diltiazem different chemometric
methods require different number of components and different
specific constraints. Also, for analysis of different samples by
the same chemometric method different models are usually
necessary to achieve better model fit conditions. This result
shows that for each sample under analysis the calibration and
prediction model always needs optimization.
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